![Isabelle Dussault](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Isabelle Dussault worked as the Global Head-Clinical Biomarker Strategy at EMD Serono, Inc. She then worked as the Senior Vice President-Research at Fusion Pharmaceuticals, Inc. for a year.
Dr. Dussault received her undergraduate and doctorate degrees from McGill University.
| Unternehmen | Position | Ende |
|---|---|---|
| FUSN PHAR | Corporate Officer/Principal | 01.04.2022 |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 3 |
|---|---|
McGill University
 McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Health Technology |
Fusion Pharmaceuticals, Inc.
 Fusion Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals for the treatment of cancer | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
